Episodios

  • NVM Cardiology Meeting Reflections: TCT 25 Wrap Up

    NVM Cardiology Meeting Reflections: TCT 25 Wrap Up
    Oct 31 2025
    In this Redcliffe Cardiology NVM reflections episode, Prof Nicolas Van Mieghem cuts through the noise from TCT 2025. Tune in to hear what the SELUTION trials mean for drug-coated balloons in de novo disease and ISR, why cost and sizing matter in calcium modification, how PE thrombectomy stacks up against anticoagulation alone, and what 7-year PARTNER 3 and 10-year NOBLE data signal for TAVR and left main PCI. Practical takeaways you can use on your next case. Drug-coated balloons (DCB): SELUTION-ISR and the large SOLUTION DeNovo RCT show non-inferiority vs contemporary care,with ~80% of DCB cases avoiding a stent. How to size, when to escalate to DES, and why 5-year data will be decisive. We also contrast these results with CAGE-FREE-1 three-year outcomes and discuss “not all DCBs are created equal.” Calcium strategies: SHORT-CUT and VICTORY pit cutting/high-pressure balloons against intravascular lithotripsy. Similar luminal results—but very different costs and workflow. We outline a toolbox and imaging-first algorithm for nodular/annular calcium and where atherectomy still fits. Pulmonary embolism: STORM-PE shows catheter thrombectomy on top of anticoagulation cuts RV/LV ratio fast along with real-world procedure times, blood loss, and complications you should counsel up front. Valves & MR: PARTNER 3 at 7 years TAVR vs surgery outcomes remain similar with reassuring valve durability; mild PVL not tied to mortality. ENCIRCLE (Sapien M3 TMVR) shows strong MR elimination but flags stroke and leaflet thrombosis prompting a rethink of antithrombotic strategy. Coronary trials: NOBLE 10-year left main results, PROCTOR (native CTO vs SVG PCI), I-MODERN (iFR-guided complete revasc vs deferred CMR), iCABG (physiology-guided grafting), INFINITY SWEDEHEART (bioadaptor stent signals), and ANDES (post-LAAO DOAC vs DAPT). Expect pragmatic thresholds, device selection tips, and critical review of the latest evidence with Prof Nicolas Van Mieghem.
    Más Menos
    33 m
  • TCT 25 Structural Interventions Highlights: Real-World Outcomes and Latest Trial Updates

    TCT 25 Structural Interventions Highlights: Real-World Outcomes and Latest Trial Updates
    Oct 29 2025
    At TCT 2025, Dr Nadira Hamid (Minneapolis Heart Institute, US) and Dr. Rahul P. Sharma (Stanford University, US) review the late-breaking trial data shaping the future of structural heart disease. The discussion highlights real-world results from TRISCEND and TRILUMINATE in tricuspid disease, 7-year PARTNER 3 durability outcomes in TAVR, national prevalence insights from the PREVUE-VALVE study, and new frontiers in mitral intervention with SUMMIT MAC. Together, they examine what the evidence means for safety, durability, patient selection, and clinical adoption. 01:05 – Tricuspid Therapies Late-breaking data from Triluminate (TriClip) and Tricend/Evoke: real-world outcomes, bleeding reduction, pacemaker trends, and patient selection. 06:40 – Aortic Valve Durability PARTNER 7-year outcomes: TAVR vs. SAVR, valve performance over time, implications for younger/lower-risk patients, and evolving device technology. 12:55 – Valvular Disease Prevalence Insights from the PREVUE-VALVE: first nationwide prevalence data, under-treatment of severe disease, and role of AI in early detection. 17:30 – Mitral Valve Advances Landmark trials: SUMMIT Trial (MAC population) and first-in-human Sapien M3 transseptal TMVR. Key outcomes, screen failure rates, and implications for clinical adoption. 24:50 – Future of Structural Heart Interventions Patient-first approach, expanding treatment options, and importance of durability and early diagnosis. For more content from TCT 2025 head to the Late-breaking Science Video Collection. Editor: Mirjam Boros Videographer: Tom Green and Dan Brent Support: This is an independent video produced by Radcliffe Cardiology.
    Más Menos
    22 m
  • View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up

    View from the Thoraxcenter: ESC 25 Late-breaking Science Wrap-Up
    Sep 15 2025
    Explore ESC 25 Top Trials with Insights from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at ESC 2025. In this comprehensive ESC wrap-up, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions. 00:15 - DOUBLE-CHOICE 04:43 - VANTAGE 07:44 - VICTOR and VICTORIA 11:29 - DIGIT-HF 14:22 - DAPA ACT HF-TIMI 68 16:55 - BETAMI-DANBLOCK and REBOOT-CNIC 22:13 - REFINE-ICD 25:34 - OPTION-STEMI 30:40 - DUAL-ACS 33:05 - NEO-MINDSET 35:58 - TARGET-FIRST 38:54 - OUTREACH 41:50 - FIRE 42:46 - AI-Gatekeeper 45:13 - POTCAST
    Más Menos
    48 m
  • View from the Thoraxcenter: What's Hot at ESC 25?

    View from the Thoraxcenter: What's Hot at ESC 25?
    Aug 8 2025
    Expert interventionalists, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) discuss the most anticipated hot line studies to be unveiled at ESC Congress 2025. Tune in for their in-depth analysis to get ahead of the curve. ESC Congress 2025 Hot Line Trials Discussed: 00:25 - DOUBLE-CHOICE 03:03 - VANTAGE 05:03 - VICTOR 06:28 - VICTORIA 07:58 - DIGIT HF 10:19 DAPA ACT HF-TIMI 68 12:35 REBOOT-CNIC 14:07 BETAMI DANBLOCK 16:03 REFINE ICD 18:05 OPTION STEMI 20:43 DUAL ACS 22:46 NEO MINDSET 24:53 TARGET FIRST 26:59 OUTREACH 29:29 FIRE 31:40 AI GATEKEEPER 22:42 LAA CLOSURE Stay tuned for Radcliffe Cardiology’s in-depth coverage of these and other pivotal trials from ESC Congress 2025.
    Más Menos
    37 m
  • Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran

    Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran
    Jun 20 2025
    Women in Cardiology: Small in Number, Large in Impact with Dr Roxana Mehran by The Radcliffe Cardiology Podcast
    Más Menos
    33 m
  • View from the Thoraxcenter: EuroPCR 25 Late-breaking Science Wrap Up

    View from the Thoraxcenter: EuroPCR 25 Late-breaking Science Wrap Up
    Jun 12 2025
    Explore the Top Trials from EuroPCR 25 with Insights from the Thoraxcenter! Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam, for an engaging and critical analysis of the latest trials unveiled at EuroPCR. In this comprehensive EuroPCR review, interventional experts examine the most significant trials, providing valuable insights into their impact on current practices and future research directions. 00:18 - UK TAVI 03:22 - ACURATE IDE 06:10 - COMPARE TAVI 07:21 - PROTECTED TAVR and BHF PROTECT TAVI Meta Analyses 11:51 - PROVISION 14:35 - REPEAT QFR 16:44 - FAITAVI 19:49 - ILIAS ANOCA 22:20 - CAREER 26:20 - RETRIEVE AMI 28:06 - ICARE-OFDI 32:28 - COMPARE-ABSORB 33:20 - BIOADAPTOR RCT 34:22 - PERFECT PSP 37:34 - bRIGHT 39:40 - TRINITY 41:45 - AMEND
    Más Menos
    44 m
  • From Women, For Women and a Legacy for Future Generations with Dr Ritu Thamman

    From Women, For Women and a Legacy for Future Generations with Dr Ritu Thamman
    Apr 4 2025
    What advice does Dr Ritu Thamman have for female cardiologists trying to navigate power dynamics within the workplace? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) are joined by Dr Ritu Thamman (University of Pittsburgh School of Medicine, PA, US) to discuss the challenges posed by queen bee syndrome and the importance of building networks to feel secure in leadership positions. Together, they also explore how institutions can improve lab safety for interventional cardiologists and pregnant women at higher risk of radiation exposure, and Dr Thamman highlights the huge disparities between standards of protection across the globe. Finally, Dr Thamman offers valuable advice to younger colleagues struggling to create an attainable work-life balance.
    Más Menos
    24 m
  • Transition of Career, Equity and Diversity in Cardiology With Dr Marta Bande

    Transition of Career, Equity and Diversity in Cardiology With Dr Marta Bande
    Mar 21 2025
    What can the transition to industry offer young cardiologists, and should they take the leap? Diversity, Inclusion and Equity in Cardiology hosts, Dr Mirvat Alasnag (King Fahad Armed Forces Hospital, Jeddah, SA) and Dr Julia Grapsa (Guy's and St Thomas' NHS Foundation Trust, London, UK) engage in an inspiring discussion with Interventional Cardiologist, Dr Marta Bande (Boston Scientific Corporation, Milan, IT). The episode dives into Dr Bande's motivations to move to industry after years in clinical practise and the skills and opportunities this exposed her to. As well as providing advice for young cardiologists contemplating changing career paths, Dr Bande talks on navigating career struggles and why she actively promotes diversity for women within cardiology.
    Más Menos
    17 m